Vitamin D Oral Gel for Prevention of Radiation Induced Oral Mucositis

NCT ID: NCT04308161

Last Updated: 2020-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-02

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this study was to evaluate clinically the effect of topical oral vitamin D gel in comparison to conventional therapy in prevention of radiation - induced oral mucositis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was designed as randomized, controlled, clinical trial. patients who were undergoing to receive radiotherapy were divided into three groups: Group I: was given conventional treatment.Group II : was given topical oral gel of vitamin D. Group III: was given topical oral gel of vitamin D in combination with the conventional treatment.

All patients were clinically evaluated at the start the radiotherapy, three weeks and six weeks later for pain and oral mucositis severity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Mucositis Due to Radiation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitamin D oral gel

Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks.

Topical oral Vitamin D gel is prepared with the aid of pharmaceutics department, faculty of pharmacy, Alexandria University. It is prepared by using Cholecalciferol 2ml ampoule (200.000 I.U.) within topical oral gel formulation.

Group Type EXPERIMENTAL

vitamin D oral gel

Intervention Type DRUG

vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis

conventional therapy

Conventional therapy (symptomatic treatment) which included:

* Miconaz oral gel
* BBC oral spray
* Oracure gel
* Alkamisr sachets

Dose: Three times a day for six weeks

Group Type ACTIVE_COMPARATOR

Miconazole Topical Gel

Intervention Type DRUG

topical anti fungal agent

BBC oral spray

Intervention Type DRUG

Topical anesthetics and anti-inflammatory agent

Oracure gel

Intervention Type DRUG

Topical analgesic gel

Alkamisr sachets

Intervention Type OTHER

Sodium bicarbonate mouthwash

combination therapy

Topical oral vitamin D gel twice daily (Equivalent to 8000 I.U/day vitamin D) for six weeks in combination with the symptomatic treatment

Symptomatic treatment which included:

* Miconaz oral gel
* BBC oral spray
* Oracure gel
* Alkamisr sachets

Symptomatic treatment dose: Three times a day for six weeks

Group Type EXPERIMENTAL

vitamin D oral gel

Intervention Type DRUG

vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis

Miconazole Topical Gel

Intervention Type DRUG

topical anti fungal agent

BBC oral spray

Intervention Type DRUG

Topical anesthetics and anti-inflammatory agent

Oracure gel

Intervention Type DRUG

Topical analgesic gel

Alkamisr sachets

Intervention Type OTHER

Sodium bicarbonate mouthwash

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vitamin D oral gel

vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis

Intervention Type DRUG

Miconazole Topical Gel

topical anti fungal agent

Intervention Type DRUG

BBC oral spray

Topical anesthetics and anti-inflammatory agent

Intervention Type DRUG

Oracure gel

Topical analgesic gel

Intervention Type DRUG

Alkamisr sachets

Sodium bicarbonate mouthwash

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are going to receive radiotherapy as a treatment of head and neck cancer either as postoperative (adjuvant) therapy or definitive therapy.
* Patients whose radiotherapy treatment planned dose is 50 Gy or above.
* Patients receiving radiotherapy alone or receiving concomitant cisplatin (or carboplatin) with radiotherapy.

Exclusion Criteria

* Patients under Anticoagulants such as warfarin, heparin, or aspirin.
* Patients whose radiotherapy treatment planned dose is lower than 50 Gy.
* Patients suffering from any uncontrolled systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction)
* Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.
* Hyper-calcemic patients.
* Smokers.
Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hams Hamed Abdelrahman

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hams Hamed Abdelrahman

Assistant lecturer

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Islam s Bakr, BDS

Role: PRINCIPAL_INVESTIGATOR

Alexandria University

azza m zaki, Phd

Role: STUDY_DIRECTOR

Alexandria University

Riham m El-Moslemany, Phd

Role: STUDY_DIRECTOR

Alexandria University

Rasha o Elsaka, Phd

Role: STUDY_DIRECTOR

Alexandria University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Outpatient clinic of Department of Clinical Oncology, Faculty of Medicine, Alexandria University

Alexandria, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Islam s Bakr, BDS

Role: CONTACT

1067809063 ext. 0020

References

Explore related publications, articles, or registry entries linked to this study.

Muanza TM, Cotrim AP, McAuliffe M, Sowers AL, Baum BJ, Cook JA, Feldchtein F, Amazeen P, Coleman CN, Mitchell JB. Evaluation of radiation-induced oral mucositis by optical coherence tomography. Clin Cancer Res. 2005 Jul 15;11(14):5121-7. doi: 10.1158/1078-0432.CCR-05-0403.

Reference Type BACKGROUND
PMID: 16033826 (View on PubMed)

Maria OM, Eliopoulos N, Muanza T. Radiation-Induced Oral Mucositis. Front Oncol. 2017 May 22;7:89. doi: 10.3389/fonc.2017.00089. eCollection 2017.

Reference Type BACKGROUND
PMID: 28589080 (View on PubMed)

Rogulj AA, Brzak BL, Boras VV, Brailo V, Milenović M. Oral complications of head and neck irradiation. Libr Oncol. 2017;45(2-3):89-93.

Reference Type BACKGROUND

Barkokebas A, Silva IH, de Andrade SC, Carvalho AA, Gueiros LA, Paiva SM, Leao JC. Impact of oral mucositis on oral-health-related quality of life of patients diagnosed with cancer. J Oral Pathol Med. 2015 Oct;44(9):746-51. doi: 10.1111/jop.12282. Epub 2014 Oct 25.

Reference Type BACKGROUND
PMID: 25345344 (View on PubMed)

Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, Pater J; National Cancer Institute of Canada Clinical Trials Group. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005 May;27(5):421-8. doi: 10.1002/hed.20162.

Reference Type BACKGROUND
PMID: 15782422 (View on PubMed)

Georgiou M, Patapatiou G, Domoxoudis S, Pistevou-Gompaki K, Papanikolaou A. Oral Mucositis: understanding the pathology and management. Hippokratia. 2012 Jul;16(3):215-6.

Reference Type BACKGROUND
PMID: 23935285 (View on PubMed)

Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004 Nov-Dec;2(6 Suppl 3):3-8.

Reference Type BACKGROUND
PMID: 15605918 (View on PubMed)

Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol. 2014 Apr 14;20(14):3751-61. doi: 10.3748/wjg.v20.i14.3751.

Reference Type BACKGROUND
PMID: 24744571 (View on PubMed)

Volpato LE, Silva TC, Oliveira TM, Sakai VT, Machado MA. Radiation therapy and chemotherapy-induced oral mucositis. Braz J Otorhinolaryngol. 2007 Jul-Aug;73(4):562-8. doi: 10.1016/s1808-8694(15)30110-5.

Reference Type BACKGROUND
PMID: 17923929 (View on PubMed)

Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016 Nov;24(11):4825-30. doi: 10.1007/s00520-016-3337-5. Epub 2016 Jul 30.

Reference Type BACKGROUND
PMID: 27475958 (View on PubMed)

Wuketich S, Hienz SA, Marosi C. Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. Support Care Cancer. 2012 Jan;20(1):175-83. doi: 10.1007/s00520-011-1107-y. Epub 2011 Feb 18.

Reference Type BACKGROUND
PMID: 21331484 (View on PubMed)

Peppone LJ, Mustian KM, Morrow GR, Dozier AM, Ossip DJ, Janelsins MC, Sprod LK, McIntosh S. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist. 2011;16(12):1784-92. doi: 10.1634/theoncologist.2011-0169. Epub 2011 Dec 1.

Reference Type BACKGROUND
PMID: 22135122 (View on PubMed)

Alongi F, Giaj-Levra N, Sciascia S, Fozza A, Fersino S, Fiorentino A, Mazzola R, Ricchetti F, Buglione M, Buonfrate D, Roccatello D, Ricardi U, Bisoffi Z. Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncol. 2017 Jul;18(7):e379-e393. doi: 10.1016/S1470-2045(17)30440-0.

Reference Type BACKGROUND
PMID: 28677574 (View on PubMed)

Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol. 2015 May;27(3):159-64. doi: 10.1097/CCO.0000000000000180.

Reference Type BACKGROUND
PMID: 25774860 (View on PubMed)

Herrstedt J. Prevention and management of mucositis in patients with cancer. Int J Antimicrob Agents. 2000 Oct;16(2):161-3. doi: 10.1016/s0924-8579(00)00232-6.

Reference Type BACKGROUND
PMID: 11053801 (View on PubMed)

Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T, Tsugane M, Hayashi N, Maeda K, Inohara H, Uejima E, Ito T. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep. 2015 Jan;33(1):33-9. doi: 10.3892/or.2014.3564. Epub 2014 Oct 23.

Reference Type BACKGROUND
PMID: 25351453 (View on PubMed)

Wink K, Brett W. [Alcoholic cardiomyopathy]. Med Monatsschr. 1976 Nov;30(11):485-9. No abstract available. German.

Reference Type BACKGROUND
PMID: 136590 (View on PubMed)

Patni N, Patni S, Bapna A. The optimal use of granulocyte macrophage colony stimulating factor in radiation induced mucositis in head and neck squamous cell carcinoma. J Cancer Res Ther. 2005 Jul-Sep;1(3):136-41. doi: 10.4103/0973-1482.19589.

Reference Type BACKGROUND
PMID: 17998644 (View on PubMed)

Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008 Jan;52(1):61-77, viii. doi: 10.1016/j.cden.2007.10.002.

Reference Type BACKGROUND
PMID: 18154865 (View on PubMed)

Cirillo N, Vicidomini A, McCullough M, Gambardella A, Hassona Y, Prime SS, Colella G. A hyaluronic acid-based compound inhibits fibroblast senescence induced by oxidative stress in vitro and prevents oral mucositis in vivo. J Cell Physiol. 2015 Jul;230(7):1421-9. doi: 10.1002/jcp.24908.

Reference Type BACKGROUND
PMID: 25536474 (View on PubMed)

Moslehi A, Taghizadeh-Ghehi M, Gholami K, Hadjibabaie M, Jahangard-Rafsanjani Z, Sarayani A, Javadi M, Esfandbod M, Ghavamzadeh A. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant. 2014 Jun;49(6):818-23. doi: 10.1038/bmt.2014.34. Epub 2014 Mar 10.

Reference Type BACKGROUND
PMID: 24614837 (View on PubMed)

Jadaud E, Bensadoun R. Low-level laser therapy: a standard of supportive care for cancer therapy-induced oral mucositis in head and neck cancer patients? Laser Ther. 2012 Dec 26;21(4):297-303. doi: 10.5978/islsm.12-RE-01.

Reference Type BACKGROUND
PMID: 24511199 (View on PubMed)

Abdel Moneim AE, Guerra-Librero A, Florido J, Shen YQ, Fernandez-Gil B, Acuna-Castroviejo D, Escames G. Oral Mucositis: Melatonin Gel an Effective New Treatment. Int J Mol Sci. 2017 May 7;18(5):1003. doi: 10.3390/ijms18051003.

Reference Type BACKGROUND
PMID: 28481279 (View on PubMed)

Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8. doi: 10.1056/NEJMoa040125.

Reference Type BACKGROUND
PMID: 15602019 (View on PubMed)

Nair R, Maseeh A. Vitamin D: The "sunshine" vitamin. J Pharmacol Pharmacother. 2012 Apr;3(2):118-26. doi: 10.4103/0976-500X.95506.

Reference Type BACKGROUND
PMID: 22629085 (View on PubMed)

Albahrani AA, Greaves RF. Fat-Soluble Vitamins: Clinical Indications and Current Challenges for Chromatographic Measurement. Clin Biochem Rev. 2016 Feb;37(1):27-47.

Reference Type BACKGROUND
PMID: 27057076 (View on PubMed)

Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague--Dawley rats. Int J Vitam Nutr Res. 1996;66(1):39-45.

Reference Type BACKGROUND
PMID: 8698545 (View on PubMed)

Adeeb F, Khan MU, Li X, Stack AG, Devlin J, Fraser AD. High Vitamin D Levels May Downregulate Inflammation in Patients with Behcet's Disease. Int J Inflam. 2017;2017:8608716. doi: 10.1155/2017/8608716. Epub 2017 Jun 4.

Reference Type BACKGROUND
PMID: 28660088 (View on PubMed)

Hassanalilou T, Khalili L, Ghavamzadeh S, Shokri A, Payahoo L, Bishak YK. Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation. Auto Immun Highlights. 2017 Dec 26;9(1):1. doi: 10.1007/s13317-017-0101-x.

Reference Type BACKGROUND
PMID: 29280010 (View on PubMed)

Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study. Carcinogenesis. 2008 Jan;29(1):93-9. doi: 10.1093/carcin/bgm240. Epub 2007 Oct 31.

Reference Type BACKGROUND
PMID: 17974532 (View on PubMed)

Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008 Jun 20;26(18):2984-91. doi: 10.1200/JCO.2007.15.1027.

Reference Type BACKGROUND
PMID: 18565885 (View on PubMed)

Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009 Feb 10;100(3):450-4. doi: 10.1038/sj.bjc.6604865. Epub 2009 Jan 20.

Reference Type BACKGROUND
PMID: 19156140 (View on PubMed)

Mokhtari Z, Hekmatdoost A, Nourian M. Antioxidant efficacy of vitamin D. J Parathyr Dis [Internet]. 2016;5(1):11-6.

Reference Type BACKGROUND

Barragan M, Good M, Kolls JK. Regulation of Dendritic Cell Function by Vitamin D. Nutrients. 2015 Sep 21;7(9):8127-51. doi: 10.3390/nu7095383.

Reference Type BACKGROUND
PMID: 26402698 (View on PubMed)

Calton EK, Keane KN, Newsholme P, Soares MJ. The Impact of Vitamin D Levels on Inflammatory Status: A Systematic Review of Immune Cell Studies. PLoS One. 2015 Nov 3;10(11):e0141770. doi: 10.1371/journal.pone.0141770. eCollection 2015.

Reference Type BACKGROUND
PMID: 26528817 (View on PubMed)

Oosterom N, Dirks NF, Heil SG, de Jonge R, Tissing WJE, Pieters R, van den Heuvel-Eibrink MM, Heijboer AC, Pluijm SMF. A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Support Care Cancer. 2019 Jan;27(1):183-190. doi: 10.1007/s00520-018-4312-0. Epub 2018 Jun 19.

Reference Type BACKGROUND
PMID: 29922939 (View on PubMed)

Christopher I, Ramsey P, Chant GR, Lockley AR, Gb W, Fields B, et al. ( 12 ) United States Patent ( 10 ) Patent No .: 2015;2(12).

Reference Type BACKGROUND

Anand A, Singh S, Sonkar AA, Husain N, Singh KR, Singh S, Kushwaha JK. Expression of vitamin D receptor and vitamin D status in patients with oral neoplasms and effect of vitamin D supplementation on quality of life in advanced cancer treatment. Contemp Oncol (Pozn). 2017;21(2):145-151. doi: 10.5114/wo.2017.68623. Epub 2017 Jun 30.

Reference Type BACKGROUND
PMID: 28947884 (View on PubMed)

World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. No abstract available.

Reference Type BACKGROUND
PMID: 24141714 (View on PubMed)

Killeen PR. An alternative to null-hypothesis significance tests. Psychol Sci. 2005 May;16(5):345-53. doi: 10.1111/j.0956-7976.2005.01538.x.

Reference Type BACKGROUND
PMID: 15869691 (View on PubMed)

Daniel W. Biostatistics. A foundation for analysis in the health science. 6th edition, NewYork: John Wiley and sons, Inc; 1995.

Reference Type BACKGROUND

Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010 Aug;126(2):619-625. doi: 10.1097/PRS.0b013e3181de24bc.

Reference Type BACKGROUND
PMID: 20679844 (View on PubMed)

Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.

Reference Type BACKGROUND
PMID: 17695343 (View on PubMed)

Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010 Mar 24;8:18. doi: 10.1186/1741-7015-8-18.

Reference Type BACKGROUND
PMID: 20334633 (View on PubMed)

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. No abstract available.

Reference Type BACKGROUND
PMID: 20332511 (View on PubMed)

Musha A, Shimada H, Shirai K, Saitoh J, Yokoo S, Chikamatsu K, Ohno T, Nakano T. Prediction of Acute Radiation Mucositis using an Oral Mucosal Dose Surface Model in Carbon Ion Radiotherapy for Head and Neck Tumors. PLoS One. 2015 Oct 29;10(10):e0141734. doi: 10.1371/journal.pone.0141734. eCollection 2015.

Reference Type BACKGROUND
PMID: 26512725 (View on PubMed)

McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006 Jun;14(6):541-7. doi: 10.1007/s00520-006-0051-8. Epub 2006 Apr 25.

Reference Type BACKGROUND
PMID: 16775649 (View on PubMed)

Vashi PG, Trukova K, Lammersfeld CA, Braun DP, Gupta D. Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J. 2010 Nov 23;9:60. doi: 10.1186/1475-2891-9-60.

Reference Type BACKGROUND
PMID: 21092237 (View on PubMed)

Scott J, Huskisson EC. Graphic representation of pain. Pain. 1976 Jun;2(2):175-84. No abstract available.

Reference Type BACKGROUND
PMID: 1026900 (View on PubMed)

McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988 Nov;18(4):1007-19. doi: 10.1017/s0033291700009934.

Reference Type BACKGROUND
PMID: 3078045 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB NO: 00010556-IORG 0008839

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omega-3 Hydrogel and Prevention of Oral Mucositis
NCT05214495 COMPLETED PHASE2/PHASE3